Clinical trials have reached an automation inflection point, according to a Fierce Pharma analysis. As protocols and data demands become more complex, the piece says traditional automation is evolving toward agentic AI—systems designed to connect workflows and accelerate execution.
The argument is that earlier tools handled discrete, isolated steps, while agentic AI acts more like a coordination layer across the trial lifecycle. The article frames this as a response to growing complexity, not simply a push for efficiency.
Because this comes from one sponsored source, the claims should be read as industry commentary rather than independent findings. No competing viewpoints are offered, though the direction described fits broader interest in applying AI to clinical operations.